Free Trial
NASDAQ:ATEC

Alphatec Q2 2025 Earnings Report

Alphatec logo
$10.98 +0.03 (+0.23%)
Closing price 07/3/2025 02:23 PM Eastern
Extended Trading
$10.98 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alphatec EPS Results

Actual EPS
N/A
Consensus EPS
-$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A

Alphatec Revenue Results

Actual Revenue
N/A
Expected Revenue
$178.85 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alphatec Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, July 30, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Alphatec Earnings Headlines

Alphatec: Continued Growth, Narrowing Losses
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Alphatec Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alphatec? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alphatec and other key companies, straight to your email.

About Alphatec

Alphatec (NASDAQ:ATEC) (NASDAQ: ATEC) is a medical technology company focused on the development and commercialization of advanced spinal surgical products. The company’s mission centers on delivering safe, reproducible, and less invasive solutions for patients undergoing spinal fusion procedures. By integrating implants, instruments, and biologics into cohesive platforms, Alphatec aims to standardize minimally invasive techniques and improve clinical outcomes.

The company’s core product portfolio includes spinal implants, surgical instruments, and biologic materials designed for minimally invasive lateral, posterior and anterior lumbar interbody fusion approaches. Alphatec’s flagship platforms—such as the Zevo lateral system and the Trestle posterior system—combine proprietary retraction, implant delivery and neuromonitoring technologies to streamline workflow while preserving soft tissue. Its biologic offerings, including synthetic ceramics and allograft extenders, support robust fusion and bone healing.

Headquartered in Carlsbad, California, Alphatec serves spine surgeons and healthcare facilities throughout the United States, Europe and select international markets. The company maintains a direct sales and clinical support organization domestically, complemented by distributor partnerships overseas. Collaborations with leading academic medical centers and participation in multicenter clinical trials underpin Alphatec’s commitment to evidence‐based innovation and global regulatory clearances.

Founded in 2013 and publicly listed in 2016, Alphatec is led by President and Chief Executive Officer Vince Forlenza, a veteran of the medical device industry, alongside Chief Financial Officer Thomas Crow. Under their stewardship, the company has pursued a strategy of targeted acquisitions, robust research and development investment, and continual expansion of its product portfolio to advance minimally invasive spine care as the standard of treatment.

View Alphatec Profile

More Earnings Resources from MarketBeat